The Latest Breaking News from MRNA

Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months'

The Trump administration is preparing to remove COVID-19 vaccines from the U.S. market "within months," according to a close associate of Health and Human Services Secretary Robert F. Kennedy Jr.

Benzinga · Aug 25, 2025

Moderna Stock Is Trading Higher Friday: What's Going On?

Moderna, Inc. (NASDAQ:MRNA) shares are trading higher Friday after the company received Health Canada approval for the updated COVID-19 vaccine.

Benzinga · Aug 22, 2025

Moderna Is Cutting 10,000 Jobs as Its Business Erodes. How Should You Play MRNA Stock Here?

With vaccine revenue crumbling and layoffs in full swing, is Moderna’s slimmed-down strategy a smart move or a red flag for investors?

Barchart · Aug 7, 2025

What's Going On With Moderna Stock Wednesday?

Moderna Inc.’s (NASDAQ:MRNA) stock has surged approximately 37% in the last month but has dipped around 15% year to date.

Benzinga · Jul 23, 2025

What to Expect From Moderna's Next Quarterly Earnings Report

Moderna is expected to announce its second-quarter results in the upcoming month, and analysts expect a slight reduction in its losses.

Barchart · Jul 14, 2025

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.

Benzinga · Jul 10, 2025

How Is Moderna’s Stock Performance Compared to Other Biotechnology Stocks?

Moderna has significantly underperformed other biotechnology stocks over the past year, and analysts remain cautious on the stock’s prospects.

Barchart · Jun 6, 2025

Moderna Stock Looks Ripe for a Short Squeeze

Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze

MarketBeat · May 22, 2025

Moderna Is the Largest of Barchart’s Bottom 100 Stocks to Buy—But Size Alone Isn’t a Reason to Invest

Moderna is the largest market cap in Barchart’s Bottom 100 Stocks to Buy. On Monday, the vaccine maker moved seven spots to the 86th position. You don’t want to make this list if you are the CEO. Here’s why.

Barchart · May 20, 2025

Moderna Stock: Analyst Estimates & Ratings

As Moderna has significantly lagged behind the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Barchart · May 8, 2025